<DOC>
	<DOCNO>NCT01703390</DOCNO>
	<brief_summary>This pilot study mount assess whether treatment assignment ERCC-1 gene expression status suggest well clinical result historical experience metastatic colorectal cancer ( mCRC ) . In wild type KRAS mCRC patient treat either FOLFOX FOLFIRI combination cetuximab median response rate approximately 60-65 % . Biomarker direct treatment study may demonstrate patient low ERCC-1 treat FOLFOX cetuximab , high ERCC-1 treat FOLFIRI cetuximab , improve response rate 70-75 % . KRAS wild type patient treat 6 cycle one follow regimen choose optimization base patient characteristic ( primary treatment phase ) . Patients ERCC-1 &lt; 1.7 relative gene expression ERCC-1 ß-actin ( ERCC-1 low ) assign treatment mFOLFOX6 combination Cetuximab . Patients ERCC-1 gene expression &gt; 1.7 relative gene expression ERCC-1 ß-actin ( ERCC-1 high ) assign treatment FOLFIRI combination Cetuximab .</brief_summary>
	<brief_title>Biomarker Directed Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1.1 Inclusion criterion prescreening phase : Untreated advanced metastatic colorectal cancer patient Adequate tissue evaluate genotyping ( 10 x 10µm thick formalin fix paraffin embed tissue section one corresponding HE stain slide FFPE tumor block ) 1.2 Inclusion criterion treatment phase : Patients must fulfill criterion list prior enrolment study : Untreated wildtype KRAS metastatic colorectal cancer Previous adjuvant therapy must complete &gt; 6 month therapy initiation study Age &gt; 18 year Measureable disease CT MRI ECOG performance status 02 Adequate organ function Hematologic : Absolute neutrophil count &gt; 1,500/µL Hemoglobin &gt; 9 mg/dl Platelet count &gt; 100,000 /µl Renal : Serum creatinine &lt; 1.5 x Upper limit normal ( UPN ) estimate clearance &gt; 30 ml/min Hepatic : Serum bilirubin &lt; 1.5 mg/dl Creatinine clearance 30 ml/min Patients history malignancy within 2 year prior study entry , except adequately treat carcinoma situ cervix ; basal squamous cell skin cancer ; low grade , early stage localize prostate cancer treat surgically curative intent ; good prognosis DCIS breast treat lumpectomy alone curative intent . Patients history severe cardiac disease ; e.g . NYHA Functional Class III IV heart failure , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina . Other known comorbidity potential dominate survival Hypersensitivity anaphylactic reaction humanize monoclonal antibody apply drug Pregnant breast feed woman Any coexist medical psychological condition would preclude participation study compromise ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>mCRC</keyword>
	<keyword>ERCC-1</keyword>
	<keyword>ERCC1</keyword>
	<keyword>AGMT</keyword>
</DOC>